Quest Pharmatech Inc V.QPT

Alternate Symbol(s): QPTFF

Healthcare Biotechnology

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

TSXV:QPT - Post by User

Quest Pharmatech Inc > What am I missing.

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Aug 24, 2021 9:48am

121 Views

Post# 33754124

RE:RE:RE:What am I missing.

Yes, Pierre did respond to my email as follows:

"I can report that the shares of OQP that are payable to OncoQuest have not been issued yet by OQP. So, OQP has approximately 78.7 million shares outstanding currently and OQP plans to issue another (approx.) 80 - 90 million shares to OncoQuest. So, in total, there will be (approx.) 165 million shares of OQP issued in total once the asset transfer shares are issued to OncoQuest and OncoQuest will become the largest shareholder of OQP."

G1945V

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions